CAR-T Cell Therapy in Multiple Myeloma & Lymphoma - Clinical Foundations

Welcome to the Oncology Brothers podcast! In this episode, we dived into the world of CAR T-cell therapy, featuring insights from hematology experts Drs. Luciano Costa and Shernan Holtan.   Join us as we explore: The basics of CAR T-cell therapy and the patient journey from referral to infusion The approved indications for CAR T-cell therapy in multiple myeloma and lymphoma, including the differences between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) The importance of holding and bridging therapies to optimize patient outcomes The evolving landscape of side effects associated with CAR T-cell therapy, including acute and chronic effects Strategies for community oncologists to better manage patient care and improve access to CAR T-cell therapies   With the potential for curative outcomes in myeloma and lymphoma, understanding these therapies is crucial for both patients and healthcare providers. Tune in for an informative discussion that aims to bridge the gap between community oncology and specialized care.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers   •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest advancements in cancer treatment! #CARTtherapy, #MultipleMyeloma, #Lymphoma, #BridgingTherapy, #OncologyBrothers